A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors

Clinical Trial ID NCT02471846

Rank	Title	Journal	Year	PubWeight™‹?›
1	Combination cancer immunotherapies tailored to the tumour microenvironment.	Nat Rev Clin Oncol	2015	1.54
2	Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.	Clin Cancer Res	2015	1.09
3	IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.	Trends Immunol	2016	0.96
4	Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.	Oncoimmunology	2016	0.84
5	Emerging therapeutic targets in metastatic progression: A focus on breast cancer.	Pharmacol Ther	2016	0.79
6	Immunobiology and immunotherapy in genitourinary malignancies.	Ann Transl Med	2016	0.78
7	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.	Clin Cancer Res	2015	0.78
8	Inflammation Models of Depression in Rodents: Relevance to Psychotropic Drug Discovery.	Int J Neuropsychopharmacol	2016	0.78
9	Pancreatic cancer: Update on immunotherapies and algenpantucel-L.	Hum Vaccin Immunother	2016	0.75